About CEL-SCI

CEL-SCI is a late-stage cancer immunotherapy company. CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in its Phase III study in advanced primary head and neck cancer patients CEL-SCI treated patients who are newly diagnosed with the investigational product Multikine* first, BEFORE they received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
 
CEL-SCI believes that this Phase III study is the largest Phase III study in the world for the treatment of head and neck cancer. Per the study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma of the head and neck were treated with the Multikine treatment regimen for 3 weeks prior to receiving the Standard of Care (SOC), which involves surgery, radiation or concurrent radiochemotherapy. Multikine is designed to help the immune system "see" the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor.

The aim of treatment with Multikine is to boost the body's immune system prior to SOC.

Topline results: The Phase III study in newly diagnosed advanced primary head and neck cancer with our Multikine immunotherapy produced a statistically significant 5-year survival benefit in patients receiving surgery plus radiotherapy. These patients represent about 40% of the study population and approximately 210,000 patients annually worldwide. The 5-year overall survival (OS) benefit in this study treatment arm was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation) Multikine arm 62.7% control arm 48.6%, survival.
 
The Company's LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment of COVID-19 in hospitalized and at-high-risk patients.

Careers

CEL-SCI's success begins and ends with its employees. The Company's progress to date reflects the talent and hard work of the individuals who conduct our lab research, manufacture our drug, manage our clinical trials and support our scientific teams. We are loyal and dedicated.  We believe that doing good can also make money. We have persevered against many difficulties and always won. Now we are at the end of the Phase 3 head and neck trial and hope to prove our novel way of treating cancer. If you want to make a difference, join our team.

Equal Opportunity Employer

CEL-SCI is proud to be an equal opportunity employer and extends employment to both women and men from culturally diverse backgrounds. We respect and value individual differences and recognize each employee as an integral member of our company. Our work force reflects these values and celebrates the individuals who make up our growing team.

CEL-SCI offers a competitive benefits package which includes:

• Medical insurance
• Dental insurance
• Vision insurance
• Long Term Disability insurance
• Life and AD&D insurance
• 401(k) Plan(each participant's contribution is matched by CEL-SCI with shares of common stock)
• Flexible Spending Accounts – FSA (which allow pre-tax deductions for dependent care, unreimbursed medical expenses and medical premiums). 
• Stock Option Plans
• Tuition Reimbursement Plan
• Vacation and Sick Leave
• AFLAC